First Time Loading...

United Therapeutics Corp
NASDAQ:UTHR

Watchlist Manager
United Therapeutics Corp Logo
United Therapeutics Corp
NASDAQ:UTHR
Watchlist
Price: 271.4303 USD -0.46% Market Closed
Updated: May 16, 2024

United Therapeutics Corp
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

United Therapeutics Corp
Interest Income Expense Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
United Therapeutics Corp
NASDAQ:UTHR
Interest Income Expense
$125.7m
CAGR 3-Years
66%
CAGR 5-Years
92%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Interest Income Expense
-$1.8B
CAGR 3-Years
8%
CAGR 5-Years
-7%
CAGR 10-Years
-19%
Gilead Sciences Inc
NASDAQ:GILD
Interest Income Expense
-$757m
CAGR 3-Years
35%
CAGR 5-Years
0%
CAGR 10-Years
-10%
Amgen Inc
NASDAQ:AMGN
Interest Income Expense
-$2.9B
CAGR 3-Years
-44%
CAGR 5-Years
-30%
CAGR 10-Years
-16%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Interest Income Expense
$563.1m
CAGR 3-Years
78%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Interest Income Expense
$221.8m
CAGR 3-Years
-13%
CAGR 5-Years
75%
CAGR 10-Years
N/A

See Also

What is United Therapeutics Corp's Interest Income Expense?
Interest Income Expense
125.7m USD

Based on the financial report for Mar 31, 2024, United Therapeutics Corp's Interest Income Expense amounts to 125.7m USD.

What is United Therapeutics Corp's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
92%

The average annual Interest Income Expense growth rates for United Therapeutics Corp have been 66% over the past three years , 92% over the past five years .